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We previously demonstrated that the proto-oncogene Pim-3 with
serine/threonine kinase activity was aberrantly expressed in cancer
cells but not in the normal cells of the pancreas. In order to elucidate
the molecular mechanism underlying aberrant Pim-3 expression in
pancreatic cancer cells, we constructed luciferase expression vectors
linked to 5′-flanking deletion mutants of the human Pim-3 gene
and transfected human pancreatic cancer cells with the resultant
vectors. The region up to –264 bp was essential for constitutive
Pim-3 gene expression, and the mutation in the Ets-1 binding site
(between –216 and –211 bp) reduced luciferase activities. Moreover,
Ets-1 mRNA and protein were constitutively expressed together
with Pim-3 in human pancreatic cancer cell lines. Chromatin
immunoprecipitation assay demonstrated constitutive binding of
Ets-1 to the 5′-flanking region of human Pim-3 gene between –249
and –183 bp. Pim-3 promoter activity and its protein expression
were induced by transfection with wild type-Ets-1 and were
reduced by transfection with dominant negative-Ets-1 or Ets-1
small-interfering RNA (siRNA). Furthermore, dominant negative-
Ets-1 and Ets-1 siRNA reduced the amount of Bad phosphorylated at
its Ser112 and induced apoptosis, when they were transfected into
human pancreatic cancer cells. Finally, Pim-3 cDNA transfection
reversed Ets-1 siRNA-induced increase in apoptosis and decrease in
Bad phosphorylation at its Ser112. These observations would indicate
that the transcription factor Ets-1 can induce aberrant Pim-3
expression and subsequently prevent apoptosis in human
pancreatic cancer cells. (Cancer Sci 2009; 100: 396–404)
Pancreatic cancer is often diagnosed at its advanced stage,when liver metastasis and peritoneal dissemination are
already evident. The prognosis is further worsened by resistance
to chemotherapy and/or radiotherapy, which are standard
treatments for advanced pancreatic cancer. Thus, pancreatic
cancer continues to be a highly fatal cancer, with less than 5%
overall 5-year survival rates.(1) Thus, a better understanding of
the molecular mechanism of pancreatic carcinogenesis and
subsequent identification of a novel molecular target are necessary
to develop novel and more effective therapeutics.
We previously observed that Pim-3, a member of the proto-
oncogene Pim family with serine/threonine kinase activity, was
aberrantly expressed in precancerous and cancerous lesions but
not normal tissues of endoderm-derived organs including the
pancreas, liver, colon, and stomach.(2–5) Other Pim family members,
Pim-1 and Pim-2, are presumed to be crucially involved in the
carcinogenesis of various organs.(6–9) Deneen and colleagues
demonstrated that Pim-3 gene transcription was enhanced in
EWS/ETS-induced malignant transformation of NIH 3T3 cells.(10)
These observations suggest that aberrantly expressed Pim-3
could contribute to carcinogenesis of endoderm-derived organs
such as the pancreas and liver. This assumption was further
supported by our previous observation that Pim-3 can inactivate
a potent proapoptotic molecule, Bad, in human pancreas and
colon carcinoma cell lines, by phosphorylating its Ser112 and
eventually promoting survival.(2,4)
Kinase activation generally requires a post-translational modi-
fication, particularly, phosphorylation in its regulatory domain.
In contrast, Pim-1 is constitutively active without any further
alteration in its conformation, probably due to its lack of any
regulatory domains.(11) Pim-3 shows a high sequence identity
with Pim-1 even in the kinase domain and also lacks any regu-
latory domains.(3) Thus, it is probable that Pim-3 can exhibit
its kinase activity when its gene product is translated after
transcription. Because gene transcription is regulated by tran-
scription factors, which bind to specific cis-elements present in
the promoter region of the target gene, the identification of the
transcription factor(s) regulating Pim-3 gene transcription can
elucidate the molecular mechanism of aberrant Pim-3 gene
expression and its protein expression during the course of
carcinogenesis.
In the present study, we tried to characterize the cis-elements
and the transcription factor(s) required for constitutive Pim-3
gene expression in human pancreatic cancer cell lines. We
revealed that the transcription factor Ets-1 constitutively bound
to the promoter region of the human Pim-3 gene and was
colocalized with Pim-3 protein in human pancreatic cancer
cells. Transfection of dominant negative Ets-1 and Ets-1 small-
interfering RNA (siRNA) decreased Pim-3 protein expression
and the amount of phospho-Ser112Bad, thereby enhancing
apoptosis. Moreover, Pim-3 cDNA transfection reversed Ets-1
siRNA-induced increase in apoptosis and decrease in Bad
phosphorylation at its Ser112. These observations suggest that
Ets-1 was involved in constitutive expression of Pim-3, a kinase
that can counteract the apoptosis of human pancreatic cancer
cells.
Materials and Methods
Cell culture and antibodies. The human pancreatic cancer cell
lines PCI35, PCI55, PCI66,(12) MiaPaca-2,(13) and PANC-1(14)
were maintained in RPMI-1640 medium, while L3.6pl(15) was
maintained in minimum essential medium (MEM) medium. All
media were supplemented with 10% fetal bovine serum (FBS)
and the cells were cultured in 5% CO2 at 37°C. The following
antibodies were used: mouse anti-Bad and rabbit anti-Ets-1
(C-20) antibodies, rabbit antiphospho-Ser112Bad antibodies,
rabbit anti-β-actin antibodies, Alexa Fluor 488 donkey antirabbit
IgG and Zenon Alexa Fluor 555 rabbit IgG labeling kits
(Molecular Probes Inc.), and Immunopure peroxidase-conjugated
goat antimouse and goat antirabbit antibodies (Pierce Biotech-
nology, Rockford, IL, USA). Rabbit anti-Pim-3 antibodies
were prepared as described previously.(4)
Plasmids. A series of Pim-3 promoter fragments were
amplified by polymerase chain reaction (PCR) using human
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genomic DNA as a template and subcloned into pGL4 firefly
luciferase reporter gene vector. The structure and fidelity of the
resulting constructs were confirmed by restriction mapping and
sequencing. Plasmids were purified using the Plasmid DNA
Purification NucleoBond PC2000 (Macherey-Nagel). At least
two independent plasmid preparations were used for each
construct in the following reporter assays. Wild-type Ets-1
(WT-Ets-1) and dominant-negative Ets-1 (DN-Ets-1) expression
vectors were a kind gift from H. Sato (Kanazawa University).
DN-Ets-1 lacks a transcription activation domain, which
corresponds to amino acid residues 306–441.(16) Human Pim-3
full-length cDNA was subcloned into pcDNA4.
Dual Luciferase reporter assay. For reporter gene assays, 1 × 105
PCI55 and MiaPaca-2 cells were cultured in a 24-well plate for
16–18 h. Then, the cells were transfected with the pGL4 vectors
containing deleted or mutated Pim-3 promoter fragment
(100 ng) by using Lipofectamine LTX and Plus (Invitrogen)
according to the manufacturer’s instructions. Transfection
efficiency was normalized by cotransfecting 5 ng of the SV40
promoter Renilla luciferase reporter gene (pRL-SV40). In some
experiments, WT-Ets-1 or DN-Ets-1 expression vector were
cotransfected together with luciferase expression vectors. Cells
were lyzed in passive lysis buffer 36 h after the transfection.
Luciferase assays were conducted with the use of the Dual
Luciferase Reporter Assay System (Promega). Firefly luciferase
values were normalized to Renilla luciferase activities and were
expressed as a fold-increase in luciferase activities compared
with pGL4 empty vector control.
RNA isolation and semiquantitative reverse transcription–PCR (RT-
PCR). Total RNAs were extracted from PCI35, PCI55, PCI66,
MiaPaca-2, PANC-1, and L3.6pl with RNA-Bee (Tel.Test,
Friends Woods, TX, USA) according to the manufacturer’s
instructions. After treatment with ribonuclease-free deoxyribonu-
clease (DNase) I, 2 μg of total RNA was reverse-transcribed at
42°C for 1 h in 20-μL reaction mixture containing mouse
moloney leukemia virus reverse transcriptase and hexanucleotide
random primers. Serially two-fold diluted cDNA products were
amplified for GAPDH (glyceraldehydes-3-phosphate dehydro-
genase) using the specific set of primers with 25 cycles of 94°C
for 30 s, 58°C for 30 s, and 72°C for 1 min in 25 μL of reaction
mixture containing Taq polymerase to evaluate the amount of the
transcribed cDNA. Then equal amounts of cDNA products were
amplified for the Pim-3 and Ets-1 genes using the following
sets of primers (Pim-3: forward primer, 5′-AAGCAGTGACC-
TCTACCCCTGGTGACC-3′, reverse primer, 5′-CAAATAAATT-
AAACAATAAATAGCCCC-3′; Ets-1: forward primer, 5′-AAGT-
CGTCACCCCAGACAAC-3′, reverse primer, 5′-TTCCTCTTT-
CCCCATCTCCT-3′) with 30 cycles of 94°C for 30 s, 58°C
for 30 s, and 68°C for 1 min. The resultant PCR products were
fractionated on 1.5% agarose gel and visualized by ethidium
bromide staining under ultraviolet light transillumination.
Immunohistochemical analysis. Human pancreatic cancer tissues
were obtained from patients upon surgery at Toyama University
Hospital for pancreatic cancer. The patients provided consent for
the use of tumor tissue for clinical research and the Toyama
University Ethical Committee approved the research protocol.
Pancreatic tissue, which was apart from the edge of tumor foci
and was judged histologically to be free from adenocarcinoma
cells, was used as a normal tissue control. Paraffin-embedded
tissue sections were deparaffinized in xylene and rehydrated
through graded concentrations of ethanol (70–100%). After
incubation with 0.3% hydrogen peroxide, sections were digested
by trypsin as antigen retrieval, followed by blocking with Non-
Specific Staining Blocking reagent (DakoCytomation, Glostrup,
Denmark). Subsequently, the slides were treated with rabbit
anti-Pim-3 IgG (3 μg/mL), followed by the incubation with
goat antirabbit IgG at room temperature for 1 h. For Ets-1
immunohistochemical staining, after deparaffinization and
rehydration, the sections were heated in a microwave in 10 mM
sodium citrate buffer (pH 6.0) for antigen retrieval. After
blockade of endogenous peroxidase and non-specific protein
binding, the slides were treated with rabbit anti-Ets-1 IgG,
followed by incubation with goat antirabbit IgG antibodies. As
a negative control, rabbit IgG was used instead of specific
primary antibodies. Then, the immunoreactivity was visualized
by using the Vectastain Elite ABC kit and Vectastain DAB
substrate kit (both Vector Laboratories). The slides were
counterstained with ChemMate Hematoxylin (Dako Cytomation),
mounted, and observed under a microscope (BX-50; Olympus,
Tokyo, Japan).
Double-color immunofluorescence analysis. Human pancreatic
cancer cell lines were seeded onto a Laboratory-Teck chamber
slide (Nalge Nunc International, Naperville, IL, USA) and
incubated at 37°C with 5% CO2. Forty-eight hours later, they
were fixed with cold acetone at –20°C for 5 min. Immunostaining
was performed by incubating the slides with rabbit polyclonal
anti-Pim-3 IgG (3 μg/mL) at 4°C, overnight, followed by
incubation with Alexa Fluor 488 donkey antirabbit antibodies
(1:100) for 1 h at room temperature in the dark. After washing
with tris-buffed saline–0.1% Tween 20 (TBS-T), the sections
were further incubated with Zenon Alexa Fluor 555–labeled
rabbit polyclonal anti-Ets-1 (2 μg/mL) for 1 h at room temperature
in the dark. Finally, the sections were washed with TBS-T and
cell images were captured on a Carl Zeiss LSM510 confocal
microscope (Carl Zeiss Microimage, Thornwood, NY, USA).
Chromatin immunoprecipitation (ChIP) assay. ChIP assay was
performed using the ChIP assay kit (Upstate, Lake Placid, NY,
USA) according to the manufacturer’s instructions. Briefly,
PCI55 cells in a subcofluent state were cross-linked with 1%
formaldehyde for 10 min at 37°C, harvested in sodium
dodecylsulfate (SDS) lysis buffer, and the chromatin was
sheared to fragments of 500 bp by sonication. Then, anti-Ets-1
polyclonal IgG or control rabbit IgG were added to each aliquot
of precleared chromatin and incubated at 4°C overnight. Then,
Protein A agarose was added to the mixtures, which were
incubated for additional 2 h at 4°C. After reversing the cross-
links, DNA was recovered by phenol–chloroform extraction and
subsequent ethanol precipitation. The resultant DNA underwent
PCR amplification using the forward primer (5′-CCAAGCG-
CAGGTCGCCTCCCGC-3′) and the reverse primer (5′-
GAAGGTCACCCGCCGGCCCCGAA-3′) to amplify a 67 bp-
long fragment corresponding to the region spanning from –
249 bp to –183 bp of the human Pim-3 promoter harboring the
Ets-1 binding site. The PCR conditions consisted of an initial
denaturation at 94°C for 5 min followed by 35 cycles of 94°C
for 30 s, 58°C for 30 s, and 68°C for 1 min, with a final
extension at 68°C for 5 min. The resultant PCR products were
fractionated on 12% polyacrylamide gel and visualized by ethidium
bromide staining under ultraviolet light transillumination.
Transient transfection and western blot analysis. Subconfluent
MiaPaca-2 cells in a 10-cm dish were transfected with either
15 μg of WT-Ets-1 or 15 μg of DN-Ets-1 expression vector by
using Lipofectamine LTX and Plus, according to the
manufacturer’s instructions. As a negative control, the cells were
transfected with 15 μg of pCEP4 empty vector. In some
experiments, MiaPaca-2 cells in a 10-cm dish were transfected
with the 100 nM (final concentration) of Ets-1 siRNA (Ambion,
siRNA ID: 115623) together with or without 10 μg of Pim-3
cDNA expression vector by using Lipofectamine 2000, according
to the manufacturer’s instructions. As a negative control, the
cells were treated with the same amount of Lipofectamin 2000.
Whole cell lysates were prepared 48 h later by using CelLytic-M
mammalian Cell Lysis/Extraction Reagent (Sigma Chemicals),
with a complete protease inhibitor cocktail (Roche Diagnostics).
After centrifugation for 15 min, aliquots (100 μg) of the obtained
supernatants were subjected to immunoblotting analysis to
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detect Bad, phosphoSer112Bad, Pim-3, Ets-1, or β-actin in a
similar way to that previously described.(2)
Cell apoptosis analysis. After transfection with either empty
vector, DN-Ets-1, WT-Ets-1 expression vectors, or Ets-1 siRNA
together with or without Pim-3 cDNA expression vector, the
cells were harvested and the phosphatidyl serine exposure level
was determined by staining the cells with the human Annexin V-
FITC Kit (Bender MedSystem), according to the manufacturer’s
instructions. At least 20 000 stained cells were analyzed on a
FACS Caliber system (Becton Dickinson, Bedford, MA, USA)
for each determination.
Statistical analysis. Data were analyzed statistically using one-
way anova followed by the Tukey–Kramer test. P < 0.05 was
considered statistically significant.
Fig. 1. Pim-3 mRNA expression in human
pancreatic cancer cell lines. (a) Semiquantitative
reverse transcription–polymerase chain reaction
(RT-PCR) analysis of Pim-3 mRNA in human
pancreatic cancer cell lines. Total RNAs were
extracted from PCI35, PCI55, PCI66, MiaPaca-2,
PANC-1, and L3.6pl cells to determine the expression
of endogenous Pim-3 at mRNA by RT-PCR.
Amplification of GAPDH (glyceraldehydes-3-
phosphate dehydrogenase) was used to confirm
that an equal amount of total RNA was used
for RT-PCR. Representative results from three
independent experiments are shown here. (b)
The nucleotide sequence of the 5′-flanking
region of the human Pim-3 gene. Putative
transcription factor binding sites are underlined.
The boundary of the first exon, putative TATA
box, and the translation initiation site are
indicated in bold and with underlining.
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Results
Characterization of 5’-flanking region of the human Pim-3 gene.
We previously reported that Pim-3 protein was constitutively
expressed in human pancreatic cancer cell lines and cancer
cells in human pancreatic cancer tissues with its predominant
localization in cytoplasm.(2) RT-PCR analysis further
demonstrated constitutive Pim-3 mRNA expression in all human
pancreatic cancer cell lines that we examined (Fig. 1a), whereas
Pim-3 mRNA was not detected in normal murine pancreas
(data not shown). Constitutive Pim-3 gene expression in human
pancreatic cancer cell lines prompted us to delineate its
molecular mechanisms in human pancreatic cancer cells. We
first cloned the human Pim-3 gene up to –2074 bp from the start
of the first exon, based on the data deposited on GenBank and
confirmed its nucleotide sequence. The human Pim-3 gene
contains canonical TATA box and contains putative binding sites
for several known transcription factors such as Stat3, Sp1, Ets-
1, NF-κB, and NF-1 (Fig. 1b). To determine the promoter
activities of 5′-flanking region of the human Pim-3 gene, we
subcloned various deleted 5′-flanking regions of the human
Pim-3 gene into a firefly luciferase reported vector (Fig. 2a, left
panel) and transiently transfected the resultant vectors into
PCI55 and Miapaca-2, two human pancreatic cancer cell lines
that constitutively express Pim-3 mRNA at different levels
(Fig. 1a). Luciferase activities were retained with the deletion
Fig. 2. Determination of promoter activities of the 5′-flanking region of the human Pim-3 gene. (a, left) Schematic structures of luciferase
expression vectors linked with various deleted 5′-flanking regions of the human Pim-3 gene. (right) Luciferase activities were determined when
the indicated luciferase vectors were transfected into PCI55 (closed boxes) or MiaPaca-2 cells (open boxes), as described in ‘Materials and Methods’.
Relative activities were calculated on the assumption that the luciferase activity was 1.0 when promoter/enhancer-less (pGL4) luciferase vector was
transfected. Mean and 1SD were calculated on three independent experiments and are shown here. (b, left) Schematic structures of luciferase
expression vectors linked with internally deleted 5′-flanking region of the Pim-3 gene. Right. Luciferase activities were determined when the
indicated luciferase vectors were transfected into PCI55 cells. Relative activities were calculated on the assumption that the luciferase activity was
1.0 when the empty pGL4 luciferase vector was transfected. Mean and 1SD were calculated for three independent experiments and are shown
here. *P < 0.05; **P < 0.01 versus p264-Luc. (c) Potential binding sites for known transcription factors, in the 5′-flanking region between –260 and
150 bp.
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below –264 bp from the start of the first exon (Fig. 2a, right
panel). By contrast, the deletion below –104 bp almost
completely abrogated enhancer activities (Fig. 2a, right panel).
We further examined the activities of p264-Luc with various
internal deletions between –264 and –115 bp (Fig. 2b, left
panel). The reporter activities were not significantly decreased
with p264Δ161-148-Luc or p264Δ146-115-Luc. On the contrary,
luciferase activities were reduced significantly with p215-Luc,
p264Δ216-178-Luc, and p264Δ178-159-Luc when they were
transfected into PCI55 cells, although the activities were still
higher than the basal activity (Fig. 2b, right panel). Similar
results were obtained when Miapaca-2 was used (data not shown).
These observations would indicate that the region between –264
and –159 bp was minimally required for constitutive Pim-3 gene
expression in human pancreatic cancer cells. This region
contains two Sp1-, one Ets-1-, and one NF-κB-binding sites
(Fig. 2c). We introduced a mutation into each potential binding
site (Fig. 3a, right panel) in p264-Luc and transfected the
resultant vectors into PCI55 cells. Luciferase activities were
reduced when the cells were transfected with p264-Luc with the
mutation in the Sp1 or Ets-1 binding site, whereas the mutation
in the NF-κB binding site had little effect on luciferase activities
(Fig. 3b). These observations would indicate that the Sp1 and
Ets-1 binding sites were operational for Pim-3 gene expression
in human pancreatic cancer cells. Sp1 is ubiquitously expressed
in normal organs including the pancreas,(17) while Ets-1 expression
was selectively enhanced in human pancreatic cancer, compared
with normal pancreatic tissue.(18) Moreover, Deneen and colleagues
demonstrated that Pim-3 gene transcription was enhanced in
EWS/ETS-mediated malignant transformation of mouse
NIH3T3 cells.(10) These observations prompted us to examine
the involvement of Ets-1 but not Sp1 in Pim-3 gene expression.
Coexpression of Ets-1 and Pim-3 proteins in human pancreatic
cancer cells and tissues. In order to define the roles of Ets-1, we
first examined Ets-1 expression in human pancreatic cancer cell
lines and tissues. Ets-1 mRNA was constitutively expressed in
all human pancreatic cancer cells that we examined (Fig. 4a),
and Ets-1 protein was detected in PCI35, PCI55, and MiaPaca-
2 cells, together with Pim-3 protein (Fig. 4b). Moreover, a
double-color immunofluorescence analysis demonstrated that
PCI55 cells constitutively expressed Ets-1 protein in the nuclei
and Pim-3 protein in the cytoplasm (Fig. 4c). Similar results
were obtained for PCI35 and MiaPaca2 cells (data not shown).
Ets-1 protein was detected faintly in normal pancreatic tissue
(Fig. 4d), consistent with the previous report.(18) In contrast, Ets-1
protein was abundantly detected in the nuclei of cancer cells in
all human pancreatic cancer tissues that we examined. Moreover,
Ets-1 and Pim-3 protein were mainly localized in the nuclei
and cytoplasm of the same cancer cells, as revealed by
immunohistochemical analysis on serial sections of human
pancreatic cancer tissues that we examined (Fig. 4e). These
observations would indicate that Ets-1 protein was constitutively
expressed in human pancreatic cancer cells, particularly in its
nuclei, and could transactivate the Pim-3 gene.
Essential contribution of Ets-1 to Pim-3 expression in human
pancreatic cancer cells. In order to prove the functionality of the
Ets-1 binding site, we conducted ChIP assays. In PCI55 cells
(Fig. 5a) and Miapaca-2 cells (data not shown), Ets-1 bound to
the 5′-flanking region of the human Pim-3 gene between –249
and –183 bp, the region that contains Ets-1 but not the Sp1-
binding site. The use of control rabbit IgG failed to give rise to
any bands, indicating the specificity of the ChIP assay. Moreover,
cotransfection with WT-Ets-1 further enhanced luciferase activities
of p264-Luc whereas that with DN-Ets-1 reduced the luciferase
activities in PCI55 cells, compared with the cells transfected
with p264-Luc alone (Fig. 5b). These observations would
indicate that Ets-1 could interact with the Ets-1 binding site of
Pim-3 gene and confer the enhancer activity.
Ets-1-mediated Pim-3 expression and subsequent apoptosis in
human pancreatic cancer cells. In order to examine whether Ets-1
could affect endogenous Pim-3 protein expression in human
pancreatic cancer cells, we transfected a human pancreatic
Fig. 3. Essential roles of the Ets-1 binding site in
Pim-3 expression. (a, left) Potential binding sites
for the known transcription factors, which are
present in the human Pim-3 gene between –267
and –158 bp region. (right) The mutation, which
was introduced into each transcription factor
binding site in p264-Luc, is indicated here. (b)
Luciferase activities were determined when the
indicated luciferase vectors were transfected into
PCI55 cells. Relative activities were calculated on
the assumption that the luciferase activity was
1.0 when empty pGL4 luciferase vector was
transfected. Mean and 1SD were calculated for
three independent experiments and are shown
here. *P < 0.05; **P < 0.01 versus p264-Luc.
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cancer cell line, MiaPaca-2, with WT-Ets-1, DN-Ets-1, or Ets-1
siRNA. WT-Ets-1 increased Pim-3 protein and the amount of
phospho-Ser112Bad (Fig. 6a). In contrast, DN-Ets-1 reduced Pim-3
protein and the amount of phospho-Ser112Bad in MiaPaca-2
cells, with little effect on the total amount of Bad protein.
Likewise, transfection with Ets-1 siRNA markedly diminished
Pim-3 protein expression and the amount of phospho-Ser112Bad
but not the total amount of Bad (Fig. 6b). Moreover, Ets-1
siRNA significantly enhanced the proportions of both early
(Annexin V-positive, PI-negative) and late (Annexin V-positive,
PI-positive) apoptotic cells, as DN-Ets-1 did (Fig. 6c). Cotrans-
fection with Pim-3 reversed the decrease in the amount of
phosphor-Ser112Bad and the increase in apoptosis induced by
Ets-1 siRNA (Fig. 6b,c). Taken together, constitutively expressed
Ets-1 in human pancreatic cancer cells can induce gene expression
and eventually protein expression of Pim-3, a serine/threonine
kinase that can regulate cell apoptosis by inactivating the
antiapoptosis molecule, Bad, through phosphorylation of its Ser112.
Discussion
We previously observed that the protein expression of the
proto-oncogene Pim-3 with serine/threonine kinase activity was
selectively enhanced in precancerous and cancerous lesions of
Fig. 4. Co-expression of Ets-1 and Pim-3 in
human pancreatic cancer cell lines and tissues. (a)
Semiquantitative reverse transcription–
polymerase chain reaction (RT-PCR) analysis of
Ets-1 mRNA in human pancreatic cancer cell lines.
Total RNAs were extracted from PCI35, PCI55,
PCI66, MiaPaca-2, PANC-1, and L3.6pl cells to
determine the expression of endogenous Ets-1
at mRNA by RT-PCR. Amplification of GAPDH
(glyceraldehydes-3-phosphate dehydrogenase)
was used to confirm that an equal amount of
total RNA was used for RT-PCR. Representative
results from three independent experiments are
shown here. (b) Constitutive expression of Ets-1
and Pim-3 protein in human pancreatic cancer
cell lines. The proteins were extracted from
PCI35, PCI55, and MiaPaca-2 cells to determine
the expression of endogenous Ets-1 and Pim-3
protein by immunoblotinng. Immunoblotting
with anti-β-actin antibodies was used to confirm
that an equal amount of protein was loaded
onto each lane. Representative results from three
independent experiments are shown here. (c) A
double-color immunofluorescence analysis was
performed on a human pancreatic cancer cell
line, PCI55, using the combination of anti-Ets-1
antibodies (red, middle panel) and anti-Pim-3
(green, left panel) as described in ‘Materials and
Methods’. The fluorescent images were digitally
merged (right panels). Representative results
from three independent experiments are shown
here. Original magnification, ×400. Scale bars,
50 μm (d) Immunohistochemical analysis was
performed on human pancreatic cancer tissues
(b, c) and normal pancreas tissues (a), using the
anti-Ets-1 antibodies (a, b, and c) as described in
‘Materials and Methods’. Representative results
from 10 samples are shown here. Original
magnification, ×200 (a); ×400 (b, c). Scale bars,
50 μm. (e) Immunohistochemical analysis on
serially sectioned human pancreatic cancer
tissues, using the anti-Ets-1 antibodies (b, d) and
anti-Pim-3 antibodies (c, e) or control rabbit IgG
(a) as described in ‘Materials and Methods’. Serial
sections from the same patient with pancreatic
ductal adenocarcinoma were used (a, b, c, d, e).
(d, e) represent box areas in (b, c) observed under
higher magnification. Representative results from
six human pancreatic cancer tissues are shown
here. Original magnification, ×200 (a, b, c); ×400
(d, e). Scale bars, 50 μm.
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endoderm-derived organs including the liver, pancreas, colon,
and stomach.(2–5) We further demonstrated that Pim-3 can
inactivate Bad by phosphorylating its Ser112, maintain the
expression of Bcl-XL, and eventually prevent apoptosis of
human pancreatic and colon cancer cells.(2,4) Protein expression
is generally controlled at various steps and the first one is
transcriptional control by a transcription factor(s). Hence, the
identification of the transcription factor(s) regulating Pim-3
gene transcription can elucidate the molecular mechanism of
aberrant Pim-3 gene expression and its subsequent protein
expression in these cancer tissues. Moreover, the clarification of
the molecular mechanism of Pim-3 protein expression can
clarify one aspect of Pim-3 activation mechanism, because its
protein expression can lead directly to its activation due to its
lack of a regulatory domain like other Pim kinase family
members.
STAT3 activities are enhanced in a wide variety of human tumors
including pancreatic cancer.(19–22) Moreover, STAT3 regulates a
number of pathways important for oncogenesis including cell
cycle progression, apoptosis, and tumor angiogenesis.(23) Of
interest is that other Pim kinase members, Pim-1 and Pim-2, are
targets for the gp130-mediated Stat3 signal in hematopoietic
cells.(24,25) Furthermore, the leukemia inhibitory factor/gp130/
Stat3 pathway enhanced the expression of Pim-3 and Pim-1,
which were indispensable for the self-renewal of mouse embry-
onic stem cells.(26) These observations raised the possibility that
STAT3 can up-regulate Pim-3 gene expression. Likewise, the
human Pim-3 gene contains several potential binding sites for
Stat3 in its 5′-flanking region. However, luciferase activities were
still retained even when Stat3 binding sites were completely
eliminated by a deletion below –264 bp. Moreover, luciferase
activity of p2074-Luc was not reduced in PCI55 cells, when the
dominant negative form of Stat3 expression vector was cotrans-
fected (our unpublished data). Thus, Stat3 may contribute little
to constitutive Pim-3 gene expression in human pancreatic
cancer cell lines.
A CD40-mediated signal induced Pim-1 gene expression in
an NF-κB-dependent manner.(27) A potential binding site for
NF-κB is present between –189 and –177 bp of the human
Pim-3 gene. Constitutive NF-κB activation in pancreatic cancer
cells(28) prompted us to investigate the role of NF-κB in Pim-3
gene expression. However, the mutation in this NF-κB binding
site failed to reduce luciferase activities; therefore, it is a remote
possibility that NF-κB contributed to constitutive Pim-3 gene
expression in human pancreatic cancer cells.
Deneen and colleagues demonstrated that Pim-3 gene tran-
scription was enhanced in the EWS/ETS-mediated malignant
transformation of mouse NIH3T3 cells.(10) EWS/ETS fusion pro-
teins retain an intact Ets DNA-binding domain and can bind to
a cis-acting site in the target genes through this domain.(29) Thus,
it is plausible that Pim-3 gene transcription can be regulated by
other Ets family members as well as EWS/ETS fusion proteins.
A major Ets family member, Ets-1, binds to specific DNA
sequences containing GGAA/T with additional flanking
nucleotides.(30) Moreover, its expression is enhanced in human
pancreatic carcinoma, compared with normal pancreatic tis-
sue.(18,31,32) Consistent with the previous reports, we also
observed that Ets-1 protein was constitutively and abundantly
expressed in the nuclei of cancer cells in the human pancreatic
cancer cell lines and tissues that we examined. Moreover, the
deletion of the Ets-1 binding site between –216 and –211 bp
reduced markedly promoter activities as revealed by luciferase
assay. Furthermore, ChIP assay demonstrated that Ets-1 bound
to the 5′-flanking region of the human Pim-3 gene between –249
and –183 bp, the region that contain Ets-1 binding site. These
observations revealed the indispensable role of Ets-1 in consti-
tutive Pim-3 gene expression. This assumption was further
supported by the observations that Pim-3 promoter activity was
reduced by transfection with DN-Ets-1. Finally, transfection
with DN-Ets-1 and Ets-1 siRNA decreased endogenous Pim-3
protein expression and subsequently induced cell apoptosis
together with reducing the amount of phosphor-Ser112Bad.
The cotransfection of Pim-3 cDNA reverted the Ets-1
siRNA-mediated decrease in the amount of phospho-Ser112Bad
and the increase in apoptosis. Thus, constitutive Ets-1 expres-
sion may counteract apoptosis in pancreatic cancer cells by
inducing the expression of Pim-3, a kinase that can inactivate
an antiapoptotic molecule, Bad, through phosphorylating its
Ser112.
Several lines of evidence suggest that enhanced Sp1 activa-
tion in K562 cells resulted in aberrant Pim-1 gene expression,(33)
and Kruppel-like factor 5 (KLF5), an Sp1-like zinc-finger protein,
can regulate Pim-1 gene expression in colon cancer cell lines.(34)
Moreover, Sp1 and Pim-3 are aberrantly activated and expressed
in pancreatic cancer tissues and cells.(2,35–37) Furthermore, we
also observed that mutation in the Sp1 binding site significantly
affected luciferase activities, suggesting that Sp1 may regulate
Pim-3 gene transcription. Of interest, Ets transcription factors
regulate their target gene expression in concert with various
transcription factors including Sp1/Sp3, AP-1, and serum
Fig. 5. Regulation of Pim-3 promoter activities
by Ets-1. (a) Determination of Ets-1 bound to the
enhancer region of the Pim-3 gene by ChIP assay.
ChIP assay was conducted on nuclear extracts
obtained from PCI55 cells, with the use of anti-Ets-1
(3 μg) or normal rabbit IgG as a negative control, as
described in Materials and Methods. Input indicates
the results when total nuclear lysates were used
without any immunoprecipitation. Representative
results from three independent experiments are
shown here. (b) The effects of the co-transfection
with WT-Ets-1 or DN-Ets-1 expression vector on the
activities of luciferase expression vectors. PCI55
cells were transfected with the p264-Luc luciferase
expression vectors, together with WT-Ets-1 or DN-Ets-1
expression vectors. Then, luciferase activities were
determined as described in Materials and Methods.
Relative activities were calculated on the
assumption that the luciferase activity was 1.0
when the pGL4 luciferase vector was transfected.
Mean and 1 SD were calculated on three
independent experiments and are shown here.
**P < 0.01 vs. transfection with p264-Luc alone.
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response factor (SRF).(30) The 5′-flanking region of the human
Pim-3 gene between –264 and +1 bp contains binding sites for
Sp1 but not AP-1 and SRF. Cooperative interactions between
Sp1 and Ets-1 have a critical role in regulating the transcription
of various genes, such as Fas ligand and the α-11 integrin
chain.(38,39) Thus, it is tempting to speculate that Sp1 may also
act cooperatively with Ets-1 to induce constitutive Pim-3 gene
expression in human pancreatic cancer cells.
In the present study, we examined the molecular mechanism
underlying constitutive Pim-3 expression in human pancreatic
cancer cells and revealed the crucial roles of Ets-1. These obser-
vations suggest that Ets-1 could be a candidate target molecule
for the treatment of pancreatic cancer.
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